Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities

SJ Tabrizi, MD Flower, CA Ross, EJ Wild - Nature Reviews Neurology, 2020 - nature.com
Huntington disease (HD) is a neurodegenerative disease caused by CAG repeat expansion
in the huntingtin gene (HTT) and involves a complex web of pathogenic mechanisms …

Insulin signaling pathway and related molecules: role in neurodegeneration and Alzheimer's disease

A Akhtar, SP Sah - Neurochemistry international, 2020 - Elsevier
Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. Its major
pathological hallmarks, neurofibrillary tangles (NFT), and amyloid-β plaques can result from …

Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions

S Bhalla, S Mehan, A Khan, MU Rehman - Neuroscience & Biobehavioral …, 2022 - Elsevier
Abstract Insulin-like growth factor-1 (IGF-1), a pleiotropic polypeptide, plays an essential role
in CNS development and maturation. Glucagon-like peptide-1 (GLP-1) is an endogenous …

[HTML][HTML] New avenues for the treatment of Huntington's disease

A Kim, K Lalonde, A Truesdell, P Gomes Welter… - International journal of …, 2021 - mdpi.com
Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG expansion in
the HD gene. The disease is characterized by neurodegeneration, particularly in the striatum …

Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease

S Franco-Iborra, A Plaza-Zabala, M Montpeyo… - Autophagy, 2021 - Taylor & Francis
The precise degradation of dysfunctional mitochondria by mitophagy is essential for
maintaining neuronal homeostasis. HTT (huntingtin) can interact with numerous other …

The role of insulin-like growth factors and insulin-like growth factor–binding proteins in the nervous system

MS Lewitt, GW Boyd - Biochemistry insights, 2019 - journals.sagepub.com
The insulin-like growth factors (IGF-I and IGF-II) and their receptors are widely expressed in
nervous tissue from early embryonic life. They also cross the blood brain barriers by active …

Current and emerging avenues for Alzheimer's disease drug targets

R Loera‐Valencia, A Cedazo‐Minguez… - Journal of internal …, 2019 - Wiley Online Library
Abstract Alzheimer's disease (AD), the most frequent cause of dementia, is escalating as a
global epidemic, and so far, there is neither cure nor treatment to alter its progression. The …

Mitochondrial dysfunction in Huntington's disease

C Carmo, L Naia, C Lopes, AC Rego - Polyglutamine disorders, 2018 - Springer
Mitochondrial dysfunction has been described as an early pathological mechanism
delineating the selective neurodegeneration that occurs in Huntington's disease (HD), a …

Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease

A Shafie, AA Ashour, S Anwar, F Anjum… - Archives of Pharmacal …, 2024 - Springer
Huntington's disease (HD) is a paradigm of a genetic neurodegenerative disorder
characterized by the expansion of CAG repeats in the HTT gene. This extensive review …

Comparative mitochondrial-based protective effects of resveratrol and nicotinamide in Huntington's disease models

L Naia, TR Rosenstock, AM Oliveira… - Molecular …, 2017 - Springer
Abstract Sirtuin 1 (SIRT1) is a nicotinamide adenine dinucleotide (NAD+)-dependent lysine
deacetylase that regulates longevity and enhances mitochondrial metabolism. Both …